237 filings
Page 2 of 12
EFFECT
nvorhk1g6zur
17 Jul 23
Notice of effectiveness
12:15am
6-K
i8oit3 3lu9s18
14 Jul 23
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
9:44am
F-1/A
fs45 4wxj
13 Jul 23
Registration statement (foreign) (amended)
5:08pm
CORRESP
kr424sthg n12
12 Jul 23
Correspondence with SEC
12:00am
F-1/A
92uvwsg
12 Jul 23
Registration statement (foreign) (amended)
12:00am
CORRESP
bo0sac6sgc6nq
12 Jul 23
Correspondence with SEC
12:00am
6-K
2xu8t ma3gm8
10 Jul 23
Current report (foreign)
8:10am
FWP
61g w7h2ae3fym13l
28 Jun 23
Free writing prospectus
8:40am
F-1/A
yga3cv5a
28 Jun 23
Registration statement (foreign) (amended)
8:37am
F-1
8ny7tvooi0lnkk1yw
16 Jun 23
Registration statement (foreign)
4:15pm
6-K
y50 54359
1 Jun 23
Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results
8:14am
6-K
4e6wey5oyur84yh tp
12 May 23
Current report (foreign)
7:00am
6-K
8uixl
11 May 23
Current report (foreign)
4:15pm
6-K
8d40 j5b2
9 May 23
Current report (foreign)
7:14am
6-K
5hupkoquo0 y04fd1yho
4 May 23
Current report (foreign)
4:15pm
6-K
vys fua6vc
4 May 23
Galmed Pharmaceuticals forms a Strategic Partnership
4:14pm
6-K
esaf n99q63bm
30 Mar 23
Current report (foreign)
4:27pm
6-K
nqcgs3huup
8 Feb 23
Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt
8:15am
6-K
qzn5t20wwe5k
5 Jan 23
Current report (foreign)
4:30pm